We use cookies to deliver our online services. Details of the cookies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you agree to our use of cookies. To close this message click close.

Hogan Lovells ILSI-Biomed Israel 2011 Luncheon

23 May 201112:30 PM - 2:00 PM (EET) Tel Aviv

In connection with this year's ILSI-Biomed Israel 2011, Hogan Lovells cordially invites you to join us for lunch and a presentation on the key issues facing the U.S. Food and Drug Administration (FDA) regulation of medical devices. Our lawyers will be happy to discuss how Hogan Lovells assists Israeli device companies and answer, as time allows, questions regarding the changing FDA device regulatory environment.

Key issues to address

Gaining FDA clearance or approval to market a new medical device in the United States is a complex and increasingly challenging process under the "New FDA." This presentation reviews the various types of FDA submissions as well as the key strategic aspects of these filings, including:

  • The Investigational Device Exemption (IDE) and the FDA requirements for clinical support for clearances and approvals of certain devices
  • The 510(k) notice and the FDA "reform" of the premarket clearance process
  • De novo downclassification
  • The Premarket Approval (PMA) application
  • The Humanitarian Device Exemption (HDE) application

In addition to the foregoing specific discussions, we will review how to successfully work with the Center for Devices and Radiological Health in this period of rapidly FDA changing policies and approaches. This will include a discussion on how to deal with difficult lead FDA reviewers and the process for appealing adverse decisions during the premarket approval/clearance processes. 

David Intercontinental Hotel
Oberjin Hall (Lobby Floor)
Tel Aviv

23 May 2011
12:30 PM - 2:00 PM (EET)

Speaker list

Loading data